Clinical trials
Hepatocellular Carcinoma Non-resectable clinical trials
Below are recruiting hepatocellular carcinoma non-resectable clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06712017Enrolling by invitation
Radioactive beads treatment for liver cancer in China
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma non-resectable?
- Yes. Clin2 currently lists 28 recruiting hepatocellular carcinoma non-resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma non-resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma non-resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.